3M CO (MMM) Factsheet
3M CO (MMM) Stock Analysis
Analysis from 10-Q filed 2025-10-21. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 16.3%. FCF margin 8.2%. D/E 3.8x. Source: 10-Q filed 2025-10-21.
| Metric | Value | Context |
|---|---|---|
| ROIC | 16.3% | Solid returns |
| FCF Margin | 8.2% | Healthy cash flow |
| Debt/Equity | 3.8x | Elevated debt |
ROIC 16.3% — Top 25% of sector peers. FCF margin 8.2% — Top 25%.
Explore 3M CO: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MMM: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: 3M CO earns 16.3% ROIC, Top 25% in Healthcare
ROIC TTM 16.3%, sector median -2.5%, Top 25%. DuPont: NOPAT margin 14.2% × asset turnover 0.7x. Gross margin 39.7%. Operating margin 19.1%. Source: 10-Q filed 2025-10-21.
| Metric | MMM | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 16.3% | Good | Above sector median of -2.5% |
| Return on Equity (ROE) | 63.8% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 39.7% | Good | Competitive pricing environment |
| Operating Margin | 19.1% | Good | Efficient operations |
Cash Flow: 3M CO generates $2.1B FCF at 8.2% margin, positive NaN/8 quarters
FCF TTM $2.1B. FCF margin 8.2%, Top 25%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-21.
| Metric | MMM | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 8.2% | Adequate | Healthy cash generation |
| Free Cash Flow (TTM) | $2.1B | Good | Positive cash generation |
| OCF/Net Income | 1.1x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: 3M CO at 3.8x leverage
Debt/Equity 3.8x. Total debt $12.6B, cash & investments $3.7B. Source: 10-Q filed 2025-10-21.
| Metric | MMM | Rating | Context |
|---|---|---|---|
| Debt to Equity | 3.8x | Red flag | Elevated leverage |
| Net Cash Position | $-8.8B | Warning | Net debt position |
Valuation: 3M CO trades at 27.8x earnings
P/E 27.8x. EV/Sales 3.4x. FCF yield 2.7%. Dividend yield 2.0%. Source: 10-Q filed 2025-10-21.
| Metric | MMM | Rating | Context |
|---|---|---|---|
| P/E Ratio | 27.8x | Adequate | Premium valuation |
| EV/Sales | 3.4x | Good | Growth premium priced in |
| FCF Yield | 2.7% | Adequate | Lower cash yield |
| Dividend Yield | 2.0% | Adequate | Growth focus over income |
Capital Allocation: 3M CO returns 7.2% shareholder yield
Total shareholder yield 7.2% (div 2.0% + buyback 5.1%). Capital returned $5.6B TTM. Source: 10-Q filed 2025-10-21.
| Metric | MMM | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 7.2% | Excellent | Dividend + buyback yield combined |
| Buyback Yield | 5.1% | Good | Active share repurchases |
| Total Capital Returned (TTM) | $5.6B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 16.3% | Top 25% | - |
| Free Cash Flow Margin | 8.2% | Top 25% | - |
| Gross Margin | 39.7% | Bottom 25% | 0.6x below |
| Operating Margin | 19.1% | Top 25% | 8.3x above |
| Return on Equity (ROE) | 63.8% | Top 10% | - |
| P/E Ratio | 27.8x | N/A | - |
Financial Scorecard
| Metric | MMM | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 16.3% | Good | Top 25% of sector (median: -2.5%) |
| Free Cash Flow Margin | 8.2% | Adequate | Top 25% of sector (median: 0.0%) |
| Gross Margin | 39.7% | Good | Bottom 25% of sector (median: 64.7%) |
| Debt to Equity Ratio | 384.8% | Red flag | High financial leverage |
| P/E Ratio (Price-to-Earnings) | 27.8x | Adequate | Growth premium |
| Free Cash Flow Yield | 2.7% | Warning | Growth-focused valuation |
Frequently Asked Questions
Q: What is 3M CO's Return on Invested Capital (ROIC)?
3M CO (MMM) has a trailing twelve-month Return on Invested Capital (ROIC) of 16.3%. Sector median -2.5%. Source: 10-Q filed 2025-10-21.
Q: What is 3M CO's Free Cash Flow Margin?
3M CO (MMM) has a free cash flow margin of 8.2%, generating $2.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-21.
Q: What is 3M CO's P/E ratio and how does it compare to peers?
3M CO (MMM) trades at a P/E ratio of 27.8x, which is above the sector median of N/A. EV/Sales 3.4x. FCF yield 2.7%. Source: 10-Q filed 2025-10-21.
Q: Does 3M CO pay a dividend?
3M CO (MMM) currently pays a dividend yield of 2.0%. Total shareholder yield (dividend + buybacks) 7.2%. Source: 10-Q filed 2025-10-21.
Q: How much debt does 3M CO have?
3M CO (MMM) has a debt-to-equity ratio of 3.8x with total debt of $12.6 billion. Net debt $8.8 billion. Source: 10-Q filed 2025-10-21.
Q: What is 3M CO's revenue and earnings growth?
3M CO (MMM) grew revenue by 2.1% year-over-year. EPS -34.5% YoY. Source: 10-Q filed 2025-10-21.
Q: Is 3M CO buying back stock?
3M CO (MMM) repurchased $4.0 billion of stock over the trailing twelve months. This represents a buyback yield of 5.1%. Source: 10-Q filed 2025-10-21.
Q: How does 3M CO compare to competitors in Healthcare?
Compared to other companies in Healthcare, 3M CO (MMM) shows: ROIC 16.3%, sector median -2.5% (Top 25%). FCF margin 8.2%, sector median 0.0% (Top 25%). Gross margin 39.7%, 25.0pp below sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with 3M CO?
Quantitative warning flags for 3M CO (MMM): 1) ROIC declining -2.0% over 8 quarters; 2) debt/equity 3.8x (above 1.5x threshold). Source: 10-Q filed 2025-10-21.
Data Source: Data sourced from 10-Q filed 2025-10-21. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.